Regeneron Pharmaceuticals, Inc. (REGN) News
Track canonical SquawkNews coverage tagged to REGN, Regeneron Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 19 indexed stories across 14 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
U.S.-China biotech rivalry drives pharma dealmaking, policy scrutiny
China has pulled ahead of the United States in two of six domains in a June Cure Innovation Index survey, while U.S. agencies and lawmakers move to screen biotech ties and licensing deals continue.
GEOPOLITICS | Aug 13, 2026, 02:41 AM UTC
H
Regeneron Stock Drops 9%
Regeneron stock falls after clinical trials
EQUITY | Aug 04, 2026, 10:36 AM UTC
L
Regeneron Awards $150,000 Prize
Regeneron awards innovation prize
EQUITY | Jul 31, 2026, 11:00 AM UTC
H
Regeneron Q2 EPS $14.29
Regeneron beats Q2 EPS estimate
EARNINGS | Jul 30, 2026, 11:52 AM UTC
H
REGN Regeneron RESULTS: Q2, Q2 ADJ EPS $14.29 vs. EST $10.3, Q2 REV $4.291B vs. EST $3.816B, Q2 EPS $12.23, Regeneron Earnings Notes:, Outlo
REGN Regeneron RESULTS: Q2, Q2 ADJ EPS $14.29 vs. EST $10.3, Q2 REV $4.291B vs. EST $3.816B, Q2 EPS $12.23, Regeneron Earnings Notes:, Outlook FY CAPEX $1,030-1.100B, Q2 dupixent global net sales rise 38% to $6B, Q2 eyle
EARNINGS | Jul 30, 2026, 10:31 AM UTC
L
REGN - Regeneron Reports Second Quarter 2026 Financial and Operating Results
REGN - Regeneron Reports Second Quarter 2026 Financial and Operating Results
EQUITY | Jul 30, 2026, 10:30 AM UTC
H
Implied EPS movers for tomorrow AM: MA +/-2.8%, VLO +/-3.9%, AEP +/-4.6%, BMY +/-3.7%, ICE +/-3.4%, REGN +/-4.3%, TT +/-7.2%, EXC +/-4.3%, P
Implied EPS movers for tomorrow AM: MA +/-2.8%, VLO +/-3.9%, AEP +/-4.6%, BMY +/-3.7%, ICE +/-3.4%, REGN +/-4.3%, TT +/-7.2%, EXC +/-4.3%, PWR +/-11.7%, ALNY +/-9.9%, XEL +/-6.3%, MO +/-3.3%, SO +/-2.0%, YUM +/-6.0%, CI
EARNINGS | Jul 29, 2026, 06:05 PM UTC
H
REGN Earnings pre-market tomorrow: qtr EPS est $10.26 (high $12.33/low $7.64), 30-day avg EPS revision -8.4% (0 analyst(s) revised up, 14 do
REGN Earnings pre-market tomorrow: qtr EPS est $10.26 (high $12.33/low $7.64), 30-day avg EPS revision -8.4% (0 analyst(s) revised up, 14 down), qtr revs est $3.82B; FY EPS est $45.74, FY revs est $15.91B; short interest
EARNINGS | Jul 29, 2026, 05:07 PM UTC
L
REGN seeing little to no movement post OTLK jumping 24% on FDA approval of Lytenava for wet AMD thus far
REGN seeing little to no movement post OTLK jumping 24% on FDA approval of Lytenava for wet AMD thus far
REGULATION | Jul 24, 2026, 06:52 PM UTC
L
BDX REGN SJM session highs
BDX REGN SJM session highs
EQUITY | Jul 14, 2026, 05:13 PM UTC
H
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
() -- Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday. As of July 6, the NYSE Arca Pharmaceutical Index
RATES | Jul 08, 2026, 03:11 PM UTC
H
Regeneron price target lowered to $769 from $778 at Truist
Truist lowered the firm's price target on Regeneron to $769 from $778 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a t
EQUITY | Jul 07, 2026, 01:13 PM UTC
H
Regeneron price target lowered to $696 from $707 at RBC Capital
RBC Capital lowered the firm's price target on Regeneron to $696 from $707 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has pick
RATES | Jul 07, 2026, 11:27 AM UTC
L
Regeneron price target lowered to $800 from $990 at HSBC
HSBC lowered the firm's price target on Regeneron to $800 from $990 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperforman
EQUITY | Jul 06, 2026, 02:25 PM UTC
H
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
The U.S. Food and Drug Administration (FDA) on Monday named seven companies selected for its FDA PreCheck Pilot Program. The initiative aims at strengthening domestic pharmaceutical manufacturing, improving the resilienc
MACRO | Jun 30, 2026, 02:17 PM UTC
M
'Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities' - CNBC
'Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities' - CNBC
REGULATION | Jun 29, 2026, 06:55 PM UTC
H
WHO: Ebola Outbreak Outpacing Response
The Ebola outbreak is continuing to outpace the response, according to WHO director Tedros.
EQUITY | Jun 24, 2026, 01:31 PM UTC
H
REGN: FDA, EMA Accept Cemdisiran Apps
Regeneron Pharmaceuticals announces FDA and EMA acceptance of regulatory applications for cemdisiran to treat generalized myasthenia gravis
EQUITY | Jun 22, 2026, 11:10 AM UTC
L
REGN - Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
REGN - Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
REGULATION | Jun 22, 2026, 11:00 AM UTC